# Phase II Clinical Study of GemOX Hepatic Arterial Infusion Combined with Lenvatinib and Toripalimab for Advanced and Unresectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer

Source: https://onco.cc/trials/nct06852287/  
OnCo record `nct06852287` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of toripalimab, gemcitabine, oxaliplatin and lenvatinib in gallbladder cancer and other biliary tract cancers, run by Tianjin Medical University Cancer Institute and Hospital, now recruiting.

## Summary

Phase II Clinical Study of GemOX Hepatic Arterial Infusion Combined with Lenvatinib and Toripalimab for Advanced and Unresectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer is a phase 2 interventional study registered as NCT06852287 by Tianjin Medical University Cancer Institute and Hospital, with a registry enrolment figure of 33 participants, started 2024-09-01 and due to reach its primary completion in 2026-09-01. Interventions recorded: chemotherapy with gemcitabine and oxaliplatin; small molecure TKI lenvatinib; immune-checkpoint inhibitor toripalimab.. Conditions listed: Intrahepatic Cholangiocarcinoma (Icc), Gall Bladder Cancer. Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: GOLD-HAIC
- Tags: ctgov-ingest; gallbladder-deep-dive
- Registry id: NCT06852287
- Phase: 2
- Setting: Phase II Clinical Study of GemOX Hepatic Arterial Infusion Combined with Lenvatinib and Toripalimab for Advanced and Unresectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer
- Sponsor: Tianjin Medical University Cancer Institute and Hospital
- Enrolled: 33

## Sources

- ClinicalTrials.gov NCT06852287: https://clinicaltrials.gov/study/NCT06852287

## Connected records

- cancers: [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Gallbladder cancer](https://onco.cc/cancers/gallbladder/), [Intrahepatic cholangiocarcinoma](https://onco.cc/cancers/intrahepatic-cholangiocarcinoma/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Platinum agents](https://onco.cc/technologies/platinum/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Lenvatinib](https://onco.cc/drugs/lenvatinib/), [Oxaliplatin](https://onco.cc/drugs/oxaliplatin/), [Toripalimab](https://onco.cc/drugs/toripalimab/)
- terms: [Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups)](https://onco.cc/terms/gallbladder-cancer-in-biliary-trials/)

---
JSON: https://onco.cc/api/v1/entities/nct06852287.json